drugset / Trial / NCT00672945

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

NCT00672945

Phase 2 Terminated 420 enrolled Epix Pharmaceuticals, Inc.
Treatment

Summary

A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.

Timeline

Start
2008-04
Primary completion
2010-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject PRX-03140 Small molecule

Indications